Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
-
MINNEAPOLIS, MN, Jan. 21, 2026 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., in cooperation with its parent PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and affiliate PetVivo AI, Inc., an...
-
Nutriband New Year Letter to Shareholders
-
-
Fentanyl designation Response
-
Revolutionary Veterinary AI Platform Ditches Dense Documentation in Favor of Clear, Engaging Video Walkthrough MINNEAPOLIS, MN, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PetVivo.ai, the AI powered platform...
-
Patients treated with 0.05% urcosimod demonstrated directionally favorable improvements in nerve fiber count and fiber length, trends not observed in the placebo groupThese findings suggest that...
-
DIMERx Appoints Lee S. Simon, MD as Chief Advisor for Clinical Development & Regulatory Strategy
-
Sangamo Therapeutics today announced that the FDA has granted Fast Track Designation to ST-503 in chronic neuropathic pain
-
Revolutionary PetVivo.ai Uses Nine AI Agents to Transform $150B Pet Care Market Important Disclaimer: This updated press release replaces and supersedes the version issued earlier this morning, which...